CHINA BIOPHARMACEUTICALS COMPLETES DESLORATADINE TRIALS.
China Biopharmaceuticals Holdings, Inc. (BULLETIN BOARD: CHBP),
Beijing, a leading Chinese pharmaceutical company focused on the
development, manufacturing and marketing of innovative drugs in . . .
DESPITE BENEFITS, GENE EXPRESSION FACES HURDLES.
The analysis of gene sequence and gene expression variations allows
for the detection of defective genes and polymorphisms associated with
specific diseases. These techniques provide the initial . . .
US FAST-TRACKS PHARMAXIS CYSTIC FIBROSIS DRUG.
Pharmaceutical company Pharmaxis (NASDAQ:PXSL), Sidney, Australia,
has announced that the US Food and Drug Administration has designated
Bronchitol as a fast-track product for cystic fibrosis.
. . .
SEMBIOSYS SIGNS PACT FOR CANGENE PLANT-PRODUCED INSULIN.
CSemBioSys Genetics Inc. (TSX:SBS), Calgary, a biotechnology
company developing a broad pipeline of protein-based pharmaceuticals and
non-pharmaceutical products, has completed a Technology . . .
TARO GETS UK MARKETING AUTHORIZATION FOR ETOPAN XL.
Taro Pharmaceutical Industries Ltd., Hawthorne, N.Y. (NASDAQ: TARO)
has reported that Taro Pharmaceuticals (UK) Limited (Taro UK), its
affiliate in the United Kingdom, has been granted a . . .
ASPERVA REPORTS ON PHASE III TRIAL FOR MYASTHENIA GRAVIS.
Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX: ASV), an
emerging pharmaceutical company focused on increasing the pool of
evidence-based medicines available for patients living with less . . .
CRUCELL/AERAS START TURBERCULOSIS VACCINE CLINICAL TRIAL.
Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL;
Swiss Exchange: CRX) has started the phase I clinical trial of the
AdVac-based tuberculosis vaccine it is developing in partnership . . .
QIAGEN UNVEILS FAST CYCLING PCR TECHNOLOGY.
QIAGEN, Venlo, Netherlands, a leading provider of products for
preanalytical sample preparation and molecular diagnostics, today
launched its new QIAGEN Fast Cycling PCR product line, . . .
BASILEA REPORTS 92% CLINICAL CURE RATES FOR CEFTOBIPROLE.
Ceftobiprole is the first anti-MRSA broad-spectrum cephalosporin to
demonstrate efficacy in a large clinical trial in patients infected with
staphylococcal infections, including . . .
TELBIVUDINE APPROVED IN SWITZERLAND FOR CHRONIC HEPATITIS
B.
Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX), Cambridge, Mass, has
announced that the Swissmedic has approved telbivudine as a new
treatment for chronic hepatitis B (CHB) in compensated patients . . .
THROMBOGENICS STARTS PHASE IIA OF MICROPLASMIN FOR
STROKE.
ThromboGenics NV (Euronext Brussels: THR), Leuven, Belgium, a
biotechnology company focused on vascular disease, has initiated a Phase
IIa clinical trial to evaluate microplasmin for the . . .
ZELOS/NEKTAR START PHASE 1 TRIAL OF INHALED OSTABOLIN-C.
Zelos Therapeutics, Inc., a private biopharmaceutical company
focused on developing novel therapies for patients suffering from
osteoporosis, and Nektar Therapeutics (Nasdaq: NKTR) have initiated . . .
ASTELLAS' SCREENING TRIGGERS MILESTONE PAYMENT TO
METABOLEX.
Metabolex, Inc., Hayward, Calif., a biotechnology company dedicated
to the discovery and development of novel therapeutics for diabetes and
related metabolic disorders, announced today that . . .
ONCOLYTICS ENROLLED FOR PHASE I SYSTEMIC DELIVERY OF
REOLYSIN.
Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY), Calgary, it has
completed patient enrolment in its Phase I U.S. clinical trial
investigating the systemic delivery of REOLYSIN(R) to treat . . .
ULTASOUND RADIOFREQUENCY USED TO TREAT HEPATIC CYSTS.
Following extensive patient studies that began in 1999, researchers
at Tang Du Hospital, Fourth Military Medical University in Xian, China,
have concluded that ultrasound-guided radiofrequency . . .
ORTHODONTIX/PROTALIX SIGN MERGER AGREEMENT.
Orthodontix, Inc. (BULLETIN BOARD: OTIX.OB) , a publicly-held
company located in Miami, Florida, and Protalix Ltd., an Israeli
biotechnology company, have entered into a definitive merger . . .
FAVORABLE PHASE 2A PHARMACOKINETIC/SAFETY DATA FOR
GLYPROMATE.
Neuren Pharmaceuticals, Sydney, Australia, has announced the
detailed pharmacokinetics analysis of the Phase 2 clinical trial of its
lead compound, Glypromate(R), for the reduction of cognitive . . .
GENZYME FILES FOR EUROPEAN APPROVAL OF SYNVISC.
Genzyme Corp. (NASDAQ:GENZ), Cambridge, Mass., has filed with the
European authority to expand the CE mark for Synvisc(R) (hylan G-F 20)
to include treatment of pain due to osteoarthritis (OA) of . . .
EVOGENE/BIOGEMMA TO DEVELOP DROUGHT TOLERANT CORN.
Evogene and Biogemma have announced a collaboration to jointly
develop commercial corn lines with improved tolerance to drought.
Corn, one of the three global crops which "feed the
world," . . .
DXS LAUNCHES LATEST GENE MUTATION TEST KIT.
Lung cancer patients who have acquired gene mutations associated
with resistance to tyrosine kinase inhibitors such as Iressa or Tarceva
can be identified far more accurately using a new mutation . . .
|
|